PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Phenotype | C0220650|brain metastases |
| Sentences | 97 |
| PubMedID- 21656328 | Triple-negative breast cancer with brain metastases is a highly selected type of cancer with very poor prognosis. |
| PubMedID- 23718256 | A retrospective database of 100 patients treated for brain metastases due to breast cancer via gamma knife radiosurgery (gks) from july 1998 through march 2009 was reviewed. |
| PubMedID- 23305997 | In her2-positive metastatic breast cancer with brain metastases not previously treated with whole brain radiotherapy, capecitabine and lapatinib combination obtains a volumetric reponse in two thirds of patients (landscape study). |
| PubMedID- 25678799 | Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated her2-positive breast cancer patient with brain metastases. |
| PubMedID- 22820413 | Regarding her2-positive breast cancer patients with established brain metastases, lapatinib (small molecule tki) seems particularly active in association with capecitabine. |
| PubMedID- 25320339 | The overall prognosis of breast cancer patients with brain metastases remains poor, and these metastases are less responsive to systemic therapies. |
| PubMedID- 24306136 | Here, we describe preclinical imaging strategies that we have used to study the development of brain metastases due to breast cancer. |
| PubMedID- 21540140 | Whole brain radiotherapy remains standard in the management of breast cancer patients with brain metastases. |
| PubMedID- 20439340 | Background: the purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (ibc). |
| PubMedID- 24390418 | Role of her2 status in the treatment for brain metastases arising from breast cancer with stereotactic radiosurgery. |
| PubMedID- 23443093 | The related evidence has mostly been based on researche about brain metastases of breast cancer. |
| PubMedID- 24932298 | By applying a well-validated nomogram, designed to predict the likelihood of subsequent brain metastases in patients with metastatic breast cancer (10), the current case report estimated the risk of brain metastases in the patient to be ~14%. |
| PubMedID- 24481998 | Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. |
| PubMedID- 21928364 | Results: we identified that kiss1 expression is significantly higher in primary breast cancer compared with brain metastases (p < .05). |
| PubMedID- 26052228 | brain metastases are common in patients with advanced breast cancer (bc), causing considerable morbidity and mortality. |
| PubMedID- 25802405 | breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. |
| PubMedID- 21424932 | breast cancers with brain metastases were of higher grade and showed higher incidence of lymph node metastases at initial diagnosis and higher egfr, p63, and ki67 expression. |
| PubMedID- 22436795 | Purpose: to elucidate survival times and identify potential prognostic factors in patients with triple-negative (tn) phenotype who harbored brain metastases arising from breast cancer and who underwent stereotactic radiosurgery (srs). |
| PubMedID- 24060578 | Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of rad51. |
| PubMedID- 20625374 | Over the past 10 years, improving the outcome of breast cancer patients with brain metastases has become an important challenge. |
| PubMedID- 23152022 | [a case of effective lapatinib/capecitabine therapy for her2-positive breast cancer with multiple brain metastases]. |
| PubMedID- 23557557 | Background: the incidence of brain metastases in patients with breast cancer is approximately 10% - 16%, and survival after diagnosis of brain metastases is usually short. |
| PubMedID- 24350786 | This report suggests that eribulin treatment may be beneficial for breast cancer patients with brain metastases progressing after whole brain radiation therapy. |
| PubMedID- 24191208 | Most clinical or preclinical data showed that lapatinib and capacitabine combination therapy is more effective than lapatinib or capacitabine monotherapy in breast cancer with brain metastases. |
| PubMedID- 23634179 | Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. |
| PubMedID- 23731980 | Thus, a new clinical trial is now recruiting patients to evaluate the efficacy of bevacizumab in breast cancer patients with active brain metastases, including its combination with trastuzumab in patients with her2 positive disease [19]. |
| PubMedID- 23047551 | Background: the clinical course of breast cancer patients with brain metastases (bm) as only metastatic site (brain-only metastatic breast cancer (bo-mbc)) has been insufficiently explored. |
| PubMedID- 22304337 | Objective: incidence of breast cancer with brain metastases (bcbm) is increasing, especially among patients over-expressing her2. |
| PubMedID- 25662600 | Consequently, the management of breast cancer patients with brain metastases clearly relies on a multidisciplinary approach, including systemic treatment. |
| PubMedID- 22741041 | In vivo magnetic resonance imaging for investigating the development and distribution of experimental brain metastases due to breast cancer. |
| PubMedID- 23011099 | Conclusion: these results suggest that lapatinib monotherapy 750 mg given twice daily can exert some efficacy and has potential as a clinically meaningful treatment option for japanese her2-overexpressing breast cancer patients with brain metastases after cranial radiation. |
| PubMedID- 20346218 | The purpose of this retrospective study was to analyze the clinical characteristics and survival of patients with brain metastases due to breast cancer of different subtypes and to identify the prognostic factors that affect clinical outcome. |
| PubMedID- 20389140 | Clinical outcomes and breast cancer subtypes in patients with brain metastases. |
| PubMedID- 26215106 | Demonstrated that among breast cancer patients with brain metastases, the patients with her2 expression had better survival compared to the patients with other molecular histologic subtypes [10]. |
| PubMedID- 21643988 | Preliminary experience of whole-brain radiation therapy (wbrt) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy. |
| PubMedID- 25156682 | Conclusion: our study showed that local brain treatments and prognosis differed by subtype in breast cancer patients with brain metastases. |
| PubMedID- 22814315 | Methods: we retrospectively evaluated clinical data from 422 breast cancer patients with brain metastases between 2001 and 2011 from referral centers in turkey. |
| PubMedID- 26055175 | Objectives: brain metastases due to breast cancer are increasing, and the prognosis is poor. |
| PubMedID- 26199252 | [a case of effective whole-brain irradiation and lapatinib/capecitabine combination therapy for her2-positive breast cancer with multiple brain metastases]. |
| PubMedID- 20604919 | In this study, brain metastases of breast cancer expressed all members of the her family of tyrosine kinase receptors. |
| PubMedID- 21929800 | breast cancer patients with brain metastases form a heterogeneous population with respect to their prognosis [14,20-26]. |
| PubMedID- 23886170 | Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients. |
| PubMedID- 24013582 | Phase i trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with her2-positive metastatic breast cancer: the laptem trial. |
| PubMedID- 25853260 | breast cancer with brain metastases in pregnancy. |
| PubMedID- 22009460 | Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer. |
| PubMedID- 22918394 | Background: in asia, large-scale studies on anti-her2 treatment in her2-positive breast cancer patients with brain metastases are limited. |
| PubMedID- 25893380 | brain metastases are frequent in patients with advanced breast cancer and are associated with poor prognosis. |
| PubMedID- 24625110 | Survival for breast cancer patients with brain metastases is poor, with a one-year survival probability of approximately 20% [2]. |
| PubMedID- 23143215 | Emerging treatment options for the management of brain metastases in patients with her2-positive metastatic breast cancer. |
| PubMedID- 23772419 | As a first example, we found that bkm120, a pi3k inhibitor that penetrates the blood-brain barrier, effectively inhibited brain metastases of her-2+ breast cancer (nanni et al., 2012). |
Page: 1 2